





Diabetes | Co-Prescription Dynamics

May 2024

A study with valuable insights

Knowledge for better health

Co-Prescription Dynamics




COMMENTS:

- The data gathered from 2,585 out of 2,910 Portuguese pharmacies indicates that in 2023, over 3 million prescriptions were issued with antidiabetic treatment drugs. Among these prescriptions, 71.2% consisted of a single antidiabetic medication, while the remaining 28.8% involved the co-prescription (Co-Rx) of multiple antidiabetic treatments simultaneously per prescription.
- The primary prescribing medical specialty in the diabetic treatment is General Practice, accounting for nearly three-quarters of all prescriptions in the country.
- Primary Health Care facilities stand as the predominant prescribing institution type, responsible for slightly over two-thirds of all antidiabetic prescriptions.

Co-Prescription Dynamics

Overall Presence of ATC 3 Classification Medicines in 2023 Antidiabetic Prescriptions




COMMENTS:

- When considering the ATC3 Classification¹, it becomes apparent that SGLT2 inhibitors were the most widely utilized therapies in 2023. They were present in 40.1% of all antidiabetic prescriptions, closely followed by Biguanides and DPP-IV Inhibitors, with 32.4% and 26.3% respectively.
- It is worth mentioning that most Biguanides are prescribed individually, while the opposite is true for Sulfonylureas, which are more often prescribed in conjunction with other antidiabetic treatments.

¹European Pharmaceutical Marketing Research Association (EPMRA). Anatomical Classification Guidelines, 2024.

Co-Prescription Dynamics

Overall Presence of Top 10 INN in 2023 Antidiabetic Prescriptions



²As per the EPHMRA Anatomical Classification Guidelines, the A10J category includes both Metformin and Metformin + Glibenclamide combinations. This clarification explains the 0.1% disparity in percentages between A10J - Biguanide antidiabetics and Metformine.

COMMENTS:

- At a more detailed level of analysis, Metformin emerges as the foremost prescribed INN in Portugal, appearing in 32.3% of all antidiabetic prescriptions. As highlighted in the preceding slide, a significant majority of these prescriptions contained solely Metformin, which on their own still substantially outweigh all other INNs, accounting for 23.2% of all antidiabetic prescriptions issued in 2023.
- The second and third most prescribed INNs are plain Dapagliflozin followed by its associated formulation with Metformin, representing the two most commonly prescribed SGLT2 inhibitors.
- In fourth place, we have Gliclazide, the primary prescribed Sulphonylurea, which, as mentioned before, is most commonly co-prescribed with other antidiabetic medications rather than being prescribed alone.

Technical File

Scope

Understand the current prescription patterns and therapeutic trends for diabetes patients.

Determine the proportion of type 2 diabetes patients already receiving optimized medication for SGLT-2 inhibitors versus those still prescribed Metformin alone or in combination with iDPP-4 inhibitors and/or Sulfonylureas.

Enhance market understanding by quantifying the most commonly antidiabetic co-prescribed drugs and identifying recurring combinations for the target products.

Period

December 2022 – November 2023

Measures & metrics

Prescriptions Issued – refers to the total count of prescriptions recorded at HMR panel pharmacies at the act of transaction, regardless of whether the medications were purchased or not.

Market Segments

Consumer health market – Dataset filtered to medicines within ATC Class “A10 – Fármacos usados na diabetes”

PT Pharmacy Total

Portuguese retail Pharmacies (mainland and Islands).

HMR Pharmacy panel

Based on a panel of 2,585 pharmacies out of a total of 2,910.

